Open Payments

The Moses H. Cone Memorial Hospital

Type
Teaching hospital
Where
Greensboro, NC
Medicare CCN
340091
Received
$1,215,163 in 192 records, 2024 ($82,670 general, $1,132,492 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment56$82,670
2024Research payment136$1,132,492

By company

CompanyRecordsAmountYears
Amgen Inc.7$272,9252024
Medtronic, Inc.11$177,2192024
CVRx, Inc.10$146,2262024
CSL Behring12$119,7332024
Merck Sharp & Dohme LLC5$96,1842024
Gilead Sciences, Inc.23$78,6122024
Edwards Lifesciences Corporation5$77,2852024
Insulet Corporation15$41,8252024
HEARTFLOW, INC.8$40,1502024
Analog Devices Inc.1$32,2842024
M.A. Med Alliance S.A.2$29,3252024
Alnylam Pharmaceuticals Inc.4$17,9952024
Caption Health, Inc.1$14,4192024
Abbott Laboratories15$13,9522024
Siemens Medical Solutions USA, Inc.7$10,2172024
PFIZER INC.23$8,8282024
Surmodics, Inc.13$7,8222024
Stryker Corporation2$6,3372024
Boehringer Ingelheim International GmbH1$3,3602024
Tandem Diabetes Care, Inc.9$3,0502024
Merz Pharmaceuticals, LLC1$3,0002024
AstraZeneca Pharmaceuticals LP2$2,6952024
iRhythm Technologies, Inc.1$2,5002024
Novartis Pharmaceuticals Corporation1$1,2002024
ARRAY BIOPHARMA INC1$1,2002024
E.R. Squibb & Sons, L.L.C.1$1,2002024
Novo Nordisk Inc1$1,0002024
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)1$1,0002024
Boehringer Ingelheim Pharmaceuticals, Inc.1$9952024
Janssen Pharmaceuticals, Inc1$7502024
Bayer Healthcare Pharmaceuticals Inc.1$5002024
Ipsen Biopharmaceuticals, Inc1$5002024
ZOLL Medical Corporation1$4002024
ConvaTec Inc.1$4002024
Olympus America Inc.2$602024
CMS Imaging, Inc.1$92024

By nature of payment

NatureRecordsAmount
Research payment136$1,132,492
Compensation for services other than consulting, including serving as faculty or as a speaker at a v31$55,575
Space rental or facility fees (teaching hospital only)17$16,470
Long term medical supply or device loan2$6,337
Education1$2,500
Grant1$1,000
Debt forgiveness3$777
Food and Beverage1$9

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31Merck Sharp & Dohme LLC$83,194Research paymentIn-kind items and services Drug, INFECTIOUS DISEASEA Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, a2024
2024-12-31Merck Sharp & Dohme LLC$11,439Research paymentIn-kind items and services Drug, INFECTIOUS DISEASEA Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,2024
2024-12-31Stryker Corporation$5,026Long term medical supply or device loanIn-kind items and servicesCORE Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$1,311Long term medical supply or device loanIn-kind items and servicesCORE Device, INSTRUMENTS2024
2024-12-31Siemens Medical Solutions USA, Inc.$717Debt forgivenessIn-kind items and services2024
2024-12-17Gilead Sciences, Inc.$2,151Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-12-17Gilead Sciences, Inc.$1,775Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-12-16PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-12-16PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-12-16PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-12-16PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-12-13HEARTFLOW, INC.$3,700Research paymentCash or cash equivalentFFRct Device, CoronaryAI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE)2024
2024-12-12Medtronic, Inc.$32,240Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2024
2024-12-12Edwards Lifesciences Corporation$30,079Research paymentCash or cash equivalentThe PROGRESS Trial 2021-012024
2024-12-12Insulet Corporation$375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-12-10Medtronic, Inc.$26,681Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2024
2024-12-10Gilead Sciences, Inc.$18,925Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-12-09Medtronic, Inc.$2,400Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2024
2024-12-06Alnylam Pharmaceuticals Inc.$14,125Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2024
2024-12-05Insulet Corporation$950Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-12-05Abbott Laboratories$684Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAbbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE)2024
2024-12-05Abbott Laboratories$684Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAbbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE)2024
2024-12-04Alnylam Pharmaceuticals Inc.$1,000Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2024
2024-11-27Analog Devices Inc.$32,284Research paymentCash or cash equivalentSensinel CPM Wearable Device, CARDIOLOGYFeasibility and Efficacy Study of the CardioPulmonary Monitoring (CPM) System in Patients with Chronic Heart Failure2024
2024-11-25Medtronic, Inc.$49,750Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2024
2024-11-21PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-11-21PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-11-19Gilead Sciences, Inc.$3,100Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-11-15Abbott Laboratories$684Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAbbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE)2024
2024-11-14Abbott Laboratories$684Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAbbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE)2024
2024-11-13Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-11-12Edwards Lifesciences Corporation$28,141Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2024
2024-11-06Abbott Laboratories$2,076Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, STRUCTURAL HEARTAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2024
2024-11-04HEARTFLOW, INC.$2,700Research paymentCash or cash equivalentFFRct Device, CoronaryAI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE)2024
2024-10-31CVRx, Inc.$8,980Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-10-31CVRx, Inc.$2,137Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-10-30Insulet Corporation$2,750Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-10-30Olympus America Inc.$17Debt forgivenessIn-kind items and services2024
2024-10-24PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-10-24Insulet Corporation$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-10-23Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-10-23Surmodics, Inc.$62Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-10-23Surmodics, Inc.$62Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-10-23Surmodics, Inc.$62Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-10-23Surmodics, Inc.$62Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-10-23Surmodics, Inc.$62Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-10-22Gilead Sciences, Inc.$6,686Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-10-22Merck Sharp & Dohme LLC$600Space rental or facility fees (teaching hospital only)Cash or cash equivalentDIFICID Drug, INFECTIOUS DISEASE2024
2024-10-16Merz Pharmaceuticals, LLC$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentXeomin Biological, Musculoskeletal2024
2024-10-16Insulet Corporation$2,250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-10-08Gilead Sciences, Inc.$550Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-10-07ZOLL Medical Corporation$400Space rental or facility fees (teaching hospital only)Cash or cash equivalentDefibrillator Device, Resuscitation2024
2024-10-04Siemens Medical Solutions USA, Inc.$2,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentsyngo Dynamics Device, SY - Image and Knowledge Management2024
2024-10-02Insulet Corporation$800Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-09-30HEARTFLOW, INC.$3,300Research paymentCash or cash equivalentFFRct Device, CoronaryAI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE)2024
2024-09-30Medtronic, Inc.$5Research paymentIn-kind items and servicesREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2024
2024-09-29Abbott Laboratories$1,368Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAbbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE)2024
2024-09-28Abbott Laboratories$1,368Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAbbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE)2024
2024-09-26Insulet Corporation$2,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-09-26Siemens Medical Solutions USA, Inc.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology2024
2024-09-26PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-09-25Surmodics, Inc.$3,000Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-09-25Surmodics, Inc.$1,500Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-09-25Surmodics, Inc.$1,000Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-09-25Surmodics, Inc.$1,000Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-09-25Surmodics, Inc.$400Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-09-25Surmodics, Inc.$400Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-09-25Surmodics, Inc.$150Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-09-20Insulet Corporation$2,025Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-09-20Alnylam Pharmaceuticals Inc.$1,875Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2024
2024-09-20Insulet Corporation$725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-09-10M.A. Med Alliance S.A.$16,825Research paymentCash or cash equivalentSELUTION SLR 018 DEB Device, CARDIOVASCULARA Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Efficacy of the SELUTION SLR 018 Drug2024
2024-09-07Ipsen Biopharmaceuticals, Inc$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentOnivyde Drug, Oncology2024
2024-08-30HEARTFLOW, INC.$2,900Research paymentCash or cash equivalentFFRct Device, CoronaryAI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE)2024
2024-08-27Gilead Sciences, Inc.$650Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-08-22Siemens Medical Solutions USA, Inc.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology2024
2024-08-21Gilead Sciences, Inc.$5,184Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-08-21Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-08-19Abbott Laboratories$786Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, STRUCTURAL HEARTAMPLATZER PFO Occluder Post Approval Study2024
2024-08-16HEARTFLOW, INC.$2,600Research paymentCash or cash equivalentFFRct Device, CoronaryAI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE)2024
2024-08-13Gilead Sciences, Inc.$1,350Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-08-09Abbott Laboratories$1,368Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAbbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE)2024
2024-08-09Abbott Laboratories$684Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAbbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE)2024
2024-08-09Bayer Healthcare Pharmaceuticals Inc.$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentNubeqa Drug, Oncology2024
2024-08-01CVRx, Inc.$12,916Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-08-01CVRx, Inc.$4,862Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-07-31Siemens Medical Solutions USA, Inc.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology2024
2024-07-25Siemens Medical Solutions USA, Inc.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology2024
2024-07-24Tandem Diabetes Care, Inc.$700Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-07-18Siemens Medical Solutions USA, Inc.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSOMATOM go.Top Device, CT and RO incl. Computed Tomography and Radiation Oncology2024
2024-07-17CVRx, Inc.$505Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-07-17PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-07-17PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-07-17PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-07-17PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-07-17PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-07-17PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-07-16Gilead Sciences, Inc.$4,144Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-07-05Amgen Inc.$103,070Research paymentIn-kind items and servicesAAHeart Lpa ChartRev2024
2024-06-30Medtronic, Inc.$45,480Research paymentIn-kind items and servicesREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2024
2024-06-28CSL Behring$10,276Research paymentCash or cash equivalentKcentra Biological, Trauma (Emergency, Injury, Surgery)A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1112024
2024-06-26Amgen Inc.$10,845Research paymentCash or cash equivalentLUMAKRAS Drug, OncologyP3 3L + Vectibix vs Pi choice CRC CB 3002024
2024-06-25Gilead Sciences, Inc.$7,699Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-06-25Insulet Corporation$2,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-06-24HEARTFLOW, INC.$4,400Research paymentCash or cash equivalentFFRct Device, CoronaryAI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE)2024
2024-06-18Gilead Sciences, Inc.$1,627Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-06-06CVRx, Inc.$70,758Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-06-06Edwards Lifesciences Corporation$16,079Research paymentCash or cash equivalentThe PROGRESS Trial 2021-012024
2024-06-03CSL Behring$90,107Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-06-03HEARTFLOW, INC.$13,000Research paymentCash or cash equivalentFFRct Device, CoronaryAI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE)2024
2024-06-03HEARTFLOW, INC.$7,550Research paymentCash or cash equivalentFFRct Device, CoronaryAI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE)2024
2024-05-28Abbott Laboratories$14Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAbbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE)2024
2024-05-24CSL Behring$2,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-05-24CSL Behring$1,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-05-24Janssen Pharmaceuticals, Inc$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentXARELTO Drug, Cardiovascular & Metabolism2024
2024-05-24CSL Behring$600Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-05-24CSL Behring$500Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-05-23Gilead Sciences, Inc.$100Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-05-21Gilead Sciences, Inc.$4,144Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-05-16Insulet Corporation$18,525Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-05-14Gilead Sciences, Inc.$1,475Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-05-13Abbott Laboratories$234Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, STRUCTURAL HEARTAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2024
2024-05-03CVRx, Inc.$14,949Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-05-03CVRx, Inc.$8,943Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-05-03Novartis Pharmaceuticals Corporation$1,200Space rental or facility fees (teaching hospital only)Cash or cash equivalentMEKINIST Drug, Oncology2024
2024-04-30Merck Sharp & Dohme LLC$300Space rental or facility fees (teaching hospital only)Cash or cash equivalentDIFICID Drug, INFECTIOUS DISEASE2024
2024-04-26Edwards Lifesciences Corporation$1,990Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-04-26PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-04-26PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-04-24M.A. Med Alliance S.A.$12,500Research paymentCash or cash equivalentSELUTION SLR 018 DEB Device, CARDIOVASCULARA Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Efficacy of the SELUTION SLR 018 Drug2024
2024-04-22Edwards Lifesciences Corporation$995Space rental or facility fees (teaching hospital only)Cash or cash equivalentSAPIEN 3 Ultra RESILIA Device, Transcatheter Heart Valves2024
2024-04-22ConvaTec Inc.$400Space rental or facility fees (teaching hospital only)Cash or cash equivalentESTEEM+ Device, OSTOMY CARE2024
2024-04-22Abbott Laboratories$14Research paymentIn-kind items and servicesFreeStyle Libre 3 Device, DIABETES CAREAbbott Freestyle LIBrE 3 Continuous glucose MonitoRing QuAlity IniTiativE (LIBERATE)2024
2024-04-20Amgen Inc.$85,386Research paymentCash or cash equivalentOCEANa-Outcomes P3 CV2024
2024-04-20Amgen Inc.$4,500Research paymentCash or cash equivalentRepatha Biological, Cardiology20170625_VESALIUS - CV2024
2024-04-19E.R. Squibb & Sons, L.L.C.$1,200Space rental or facility fees (teaching hospital only)Cash or cash equivalentOPDIVO Biological, Oncology2024
2024-04-19ARRAY BIOPHARMA INC$1,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-04-19Merck Sharp & Dohme LLC$650Space rental or facility fees (teaching hospital only)Cash or cash equivalentVERQUVO Drug, CARDIOVASCULAR2024
2024-04-17Boehringer Ingelheim Pharmaceuticals, Inc.$995Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-04-17Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-04-16Gilead Sciences, Inc.$4,668Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-04-16Gilead Sciences, Inc.$600Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-04-11Alnylam Pharmaceuticals Inc.$995Space rental or facility fees (teaching hospital only)Cash or cash equivalentAMVUTTRA Drug, Genetic Disease2024
2024-04-02Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-03-31Medtronic, Inc.$6,501Research paymentIn-kind items and servicesREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2024
2024-03-29Olympus America Inc.$43Debt forgivenessIn-kind items and services2024
2024-03-28AstraZeneca Pharmaceuticals LP$995Space rental or facility fees (teaching hospital only)Cash or cash equivalentFARXIGA Drug, Cardiovascular and Metabolism2024
2024-03-27Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-03-25Amgen Inc.$8,153Research paymentIn-kind items and servicesRepatha Biological, Cardiology20170625_VESALIUS - CV2024
2024-03-25CMS Imaging, Inc.$9Food and BeverageCash or cash equivalent2024
2024-03-22CSL Behring$10,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-03-22Insulet Corporation$2,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-03-22CSL Behring$2,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-03-22CSL Behring$1,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-03-22CSL Behring$1,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-03-22CSL Behring$900Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-03-22CSL Behring$350Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-03-21Insulet Corporation$4,775Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2024
2024-03-20Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-03-19Gilead Sciences, Inc.$1,556Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-03-18PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-03-18PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-03-18Medtronic, Inc.$450Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2024
2024-02-27Gilead Sciences, Inc.$100Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-02-22Gilead Sciences, Inc.$5,184Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-02-19Abbott Laboratories$2,801Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, STRUCTURAL HEARTAMPLATZER PFO Occluder Post Approval Study (PFO PAS)2024
2024-02-16AstraZeneca Pharmaceuticals LP$1,700Research paymentCash or cash equivalentIMFINZI Biological, OncologyA Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab2024
2024-02-16Surmodics, Inc.$62Research paymentCash or cash equivalentSurVeil Drug-Coated Balloon Device, Drug Coated BalloonSafety and Efficacy of the SurVeil Drug-Coated Balloon (TRANSCEND)2024
2024-02-15PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15Medtronic, Inc.$375Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2024
2024-02-15PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-12Abbott Laboratories$500Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, STRUCTURAL HEARTOSB Lead-AMPLATZERPFOOccluder New EnrollmentPAS2024
2024-02-01Gilead Sciences, Inc.$700Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-01-31Amgen Inc.$40,426Research paymentIn-kind items and servicesRepatha Biological, CardiologyACS-REAL Pragmatic study EVOLVE MI2024
2024-01-31Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-01-25Novo Nordisk Inc$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-01-24CVRx, Inc.$12,249Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-01-24ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)$1,000GrantCash or cash equivalentLifeVest Device, Electromedical and Electrotherapeutic Apparatus2024
2024-01-23iRhythm Technologies, Inc.$2,500EducationCash or cash equivalentZIO XT Patch Device, Cardiology/Vascular Diseases2024
2024-01-22Medtronic, Inc.$525Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringDefine AFib2024
2024-01-18CVRx, Inc.$9,925Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-01-18Gilead Sciences, Inc.$4,144Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-01-17Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-01-10Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-01-08Amgen Inc.$20,544Research paymentIn-kind items and servicesOCEANa-Outcomes P3 CV2024
2024-01-04Boehringer Ingelheim International GmbH$3,360Research paymentCash or cash equivalentJARDIANCE Drug, DIABETESEmpagliflozin for prevention of HHF and death after an AMI2024
2024-01-02Medtronic, Inc.$12,812Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2024
2024-01-02Gilead Sciences, Inc.$2,100Research paymentCash or cash equivalentA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2024
2024-01-01Caption Health, Inc.$14,419Research paymentCash or cash equivalent Device, Lung GuidanceLung Guidance2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Guilford CountyGreensboro city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Greensboro, NC, county Guilford County, NC, state North Carolina; placed by its city name.

MeasurePlace (city or town)
Greensboro, NC
County
Guilford County, NC
State
North Carolina
Population B01003301,198547,94010,730,404
Population, 2020 census P1299,035541,29910,439,388
Median age B0100234.337.539.1
Under 18 B0100121.7%22.0%21.8%
65 and over B0100114.4%15.9%17.2%
Households B11001123,984219,7184,282,345
Foreign born B0500212.7%11.8%9.1%
Median household income B19013$61,515$68,642$72,388
Median family income B19113$80,585$88,156$90,290
Per capita income B19301$37,531$39,376$41,385
Poverty rate B1700117.0%14.6%13.0%
Unemployment rate B230255.1%4.6%4.7%
Civilian labor force B23025158,568282,3625,336,863
Mean commute (minutes) B0801321.722.025.1
Bachelor's degree or higher B1500341.0%39.0%35.7%
Housing units B25001135,665238,0324,895,668
Owner-occupied B2500350.5%59.9%66.6%
Renters B2500349.5%40.1%33.4%
Median home value B25077$244,800$259,900$288,900
Median gross rent B25064$1,172$1,163$1,228
White, not Hispanic B0300238.1%46.0%60.0%
Black B0300241.0%33.5%20.0%
Hispanic or Latino B0300210.5%10.1%11.3%
Asian B030025.2%5.4%3.3%
American Indian and Alaska Native B030020.2%0.1%0.8%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greensboro, NC.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.